N-(2,2-difluoroethyl)-1-((6-(difluoromethoxy)-5-methylpyrimidin-4-yl)methyl)-6-methoxy-1H-pyrrolo[3,2-b]pyridine-3-carboxamide | 1615713-96-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 英文名称: N-(2,2-difluoroethyl)-1-((6-(difluoromethoxy)-5-methylpyrimidin-4-yl)methyl)-6-methoxy-1H-pyrrolo[3,2-b]pyridine-3-carboxamide
• 英文别名: N-(2,2-difluoroethyl)-1-[[6-(difluoromethoxy)-5-methyl-pyrimidin-4-yl]methyl]-6-methoxy-pyrrolo[3,2-b]pyridine-3-carboxamide；N-(2,2-difluoroethyl)-1-[[6-(difluoromethoxy)-5-methylpyrimidin-4-yl]methyl]-6-methoxypyrrolo[3,2-b]pyridine-3-carboxamide
• CAS: 1615713-96-6
• 化学式: C₁₈H₁₇F₄N₅O₃
• 分子量: 427.358
• InChiKey: GHFQIHVUEACSQS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  30
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  91.2
• 氢给体数：
  1
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  2-氯-5-甲氧基-3-硝基吡啶 在 1-甲基吡咯烷 、 铁粉 、 sodium hydride 、 溶剂黄146 、 1-丙基磷酸酐 、 三乙胺 、 lithium chloride 、 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 水 、 二甲基亚砜 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 生成 N-(2,2-difluoroethyl)-1-((6-(difluoromethoxy)-5-methylpyrimidin-4-yl)methyl)-6-methoxy-1H-pyrrolo[3,2-b]pyridine-3-carboxamide
  参考文献：
  名称：

  Lead Optimization of 1,4-Azaindoles as Antimycobacterial Agents

  摘要：

  In a previous report, we described the discovery of 1,4-azaindoles, a chemical series with excellent in vitro and in vivo antimycobacterial potency through noncovalent inhibition of decaprenylphosphoryl-beta-D-ribose-2'-epimerase (DprE1). Nevertheless, high mouse metabolic turnover and phosphodiesterase 6 (PDE6) off-target activity limited its advancement. Herein, we report lead optimization of this series, culminating in potent, metabolically stable compounds that have a robust pharmacokinetic profile without any PDE6 liability. Furthermore, we demonstrate efficacy for 1,4-azaindoles in a rat chronic TB infection model. We believe that compounds from the 1,4-azaindole series are suitable for in vivo combination and safety studies.

  DOI：

  10.1021/jm500571f

文献信息

• AZAINDOLE COMPOUNDS, SYNTHESIS THEREOF, AND METHODS OF USING THE SAME
  申请人：Global Alliance for TB Drug Development

  公开号：US20150025087A1

  公开（公告）日：2015-01-22

  The invention provides compounds of formula (I) and methods of treating a Mycobacterium infection or tuberculosis, or inhibiting DprE1 with the same.

  该发明提供了式（I）的化合物以及用于治疗结核分枝杆菌感染或肺结核，或者用于抑制DprE1的方法。
• US9163020B2
  申请人：——

  公开号：US9163020B2

  公开（公告）日：2015-10-20
• [EN] AZAINDOLE COMPOUNDS, SYNTHESIS THEREOF, AND METHODS OF USING THE SAME<br/>[FR] COMPOSÉS D'AZA-INDOLE, LEUR SYNTHÈSE ET PROCÉDÉS POUR LES UTILISER
  申请人：GLOBAL ALLIANCE FOR TB DRUG DEV

  公开号：WO2015009525A1

  公开（公告）日：2015-01-22

  The invention provides compounds of formula (I) and methods of treating a Mycobacterium infection or tuberculosis, or inhibiting DprE1 with the same.
• Lead Optimization of 1,4-Azaindoles as Antimycobacterial Agents
  作者：Pravin S. Shirude、Radha K. Shandil、M. R. Manjunatha、Claire Sadler、Manoranjan Panda、Vijender Panduga、Jitendar Reddy、Ramanatha Saralaya、Robert Nanduri、Anisha Ambady、Sudha Ravishankar、Vasan K. Sambandamurthy、Vaishali Humnabadkar、Lalit K. Jena、Rudrapatna S. Suresh、Abhishek Srivastava、K. R. Prabhakar、James Whiteaker、Robert E. McLaughlin、Sreevalli Sharma、Christopher B. Cooper、Khisi Mdluli、Scott Butler、Pravin S. Iyer、Shridhar Narayanan、Monalisa Chatterji

  DOI：10.1021/jm500571f

  日期：2014.7.10

  In a previous report, we described the discovery of 1,4-azaindoles, a chemical series with excellent in vitro and in vivo antimycobacterial potency through noncovalent inhibition of decaprenylphosphoryl-beta-D-ribose-2'-epimerase (DprE1). Nevertheless, high mouse metabolic turnover and phosphodiesterase 6 (PDE6) off-target activity limited its advancement. Herein, we report lead optimization of this series, culminating in potent, metabolically stable compounds that have a robust pharmacokinetic profile without any PDE6 liability. Furthermore, we demonstrate efficacy for 1,4-azaindoles in a rat chronic TB infection model. We believe that compounds from the 1,4-azaindole series are suitable for in vivo combination and safety studies.